Brentuximab vedotin in transplant-naïve patients with relapsed or refractory Hodgkin lymphoma: Analysis of two phase I studies

Oncologist

Volumn 17, Issue 8, 2012, Pages 1073-1080

  Forero Torres, Andres ^a   Fanale, Michelle ^b   Advani, Ranjana ^c   Bartlett, Nancy L ^d   Rosenblatt, Joseph D ^e   Kennedy, Dana A ^f   Younes, Anas ^b  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MIAMI   (United States)

^f SEATTLE GENETICS INC   (United States)

Author keywords

Antigens CD30; Hodgkin disease; Immunoconjugates; Monoclonal antibodies

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CISPLATIN; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHYLPREDNISOLONE; MOCETINOSTAT; NAVELBINE; RITUXIMAB; VINBLASTINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACKACHE; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CHILD; CHILL; CLINICAL ARTICLE; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HODGKIN DISEASE; HUMAN; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NIGHT SWEAT; OPEN STUDY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD30; CHILD; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGOPEPTIDES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84865235209     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0133     Document Type: Article

References (25)

1. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484.
2. Diehl V, Franklin J, PfreundschuhMet al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395.
3. Josting A, Franklin J, May M et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002;20:221-230.
4. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993;341:1051-1054.
5. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002;359:2065-2071.
6. Andre M, Henry-Amar M, Pico JL et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study. J Clin Oncol 1999;17:222-229.
7. Baetz T, Belch A, Couban S et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003;14:1762-1767.
8. Bonfante V, Viviani S, Devizzi L et al. High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. Eur J Haematol 2001;66(Suppl 64):51-55.
9. Josting, A, Rudolph C, Reiser M et al. Time-intensified dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002;13:1628-1635.
10. Chau I, Harries M, Cunningham D et al. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol 2003;120:970-977.
11. Ferme C, Mounier N, DivineMet al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002;20:467-475.
12. Byrne BJ, Gockerman JP. Salvage therapy in Hodgkin's lymphoma. The Oncologist 2007;12:156-167.
13. Ardeshna KM, Kakouros N, QianWet al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol 2005;130:363-372.
14. Sutherland MS, Sanderson RJ, Gordon KA et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006;281: 10540-10547.
15. Francisco JA, Cerveny CG, Meyer DL et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-1465.
16. Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-1821.
17. Fanale MA, Forero-Torres A, Rosenblatt JD et al. A phase 1 weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012;18:248-255.
18. Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-2189.
19. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
20. Colwill R, Crump M, Couture F et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995;13:396-402.
21. Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model. Blood 2001;97:616-623.
22. Bartlett NL, Niedzwiecki D, Johnson JL et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18:1071-1079.
23. Gopal AK, Press OW, Shustov AR et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: A prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 2010;51:1523-1529.
24. Lee, JJ, SM Swain. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24: 1633-1642.
25. Swain, SM, JC Arezzo. Neuropathy associated with microtubule inhibitors: Diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008;6: 455-467.